Catalent has announced that Dr. Donald E. Morel will be added to its Board of Directors, effective the next time the Board convenes, increasing the size of the Board to ten members.
Dr. Morel retired in June 2015 as Chairman of West Pharmaceutical Services, Inc. (“West”), a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, a position he had held since March 2003. He also served as West’s Chief Executive Officer from April 2002 until April 2015 and as its President from April 2002 until June 2005.
Currently, Dr. Morel serves as Chairman of the Board of Directors of the American Oncologic Hospital of the Fox Chase Cancer Center. He also serves as Chairman of the Board of Trustees of the Franklin Institute and is a Trustee of Lafayette College. Additionally, Dr. Morel has been a Director of Integra Life Sciences Holdings Corporation since August 2013. Prior to that, he served as a Director of Kensey Nash Corporation from 2010 until 2012.
John Chiminski, President and Chief Executive Officer of Catalent, Inc., said, “We are extremely excited to be able to strengthen our Board with yet another pharmaceutical services veteran. Don has a proven track record of executive leadership and strategic vision, having grown West into a universally recognized name in the market. We look forward to his many insightful contributions toward enhancing Catalent’s market leadership.”
“Having seen first hand Catalent’s significant value proposition, I am excited by the opportunity to leverage my years of industry experience, alongside an already impressive Board, to help Catalent capitalize on its many opportunities for growth,” commented Dr. Morel.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.